On July 15, InnoCare Pharma rose 5.09% in regular trading, trading at HK$15.04 per share, with turnover of HK$67.34 million.

The gain was driven by a broad-based rally in the biotech sector alongside company-specific catalysts. On the sector front, SKB Bio rose 10.2%, Akeso rose 7.98%, Innovent Bio rose 7.66%, 3SBio rose 6.56%, and BeiGene rose 2.37%. At the company level, InnoCare's self-developed CDH17-targeting ADC drug ICP-B208 completed first patient dosing, with clinical data recently published in an international academic journal. ICP-B208 is a novel ADC utilizing a proprietary technology platform, and no CDH17-targeted ADC has yet been approved globally. Additionally, 2,044,750 new shares from the company's 2023 restricted stock incentive plan became listed for trading today, following completion of share registration for the third vesting period of initial grants and second vesting period of reserved grants.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)